CTLA4 and neuroblastoma: Therefore, we inoculated the 8-week pMMR or idMMR neuroblastoma cells into A/J immunocompetent mice and treated them with anti-PD1, anti-CTLA4, or a combination of both antibodies (Figure 5A).